Tango Therapeutics Q1 net loss $39.9M; cash runway extended to Q1 2027; TNG462 data update 2H2025

Tango Therapeutics, Inc.

2025-Q1 EPS reported -$0.36 revenue$5,392,000

Net loss of $39.9M ($0.36/share) for Q1 2025 vs $37.9M ($0.35/share) in Q1 2024.
Cash of $216.7M; runway extended into Q1 2027 via reduction in preclinical spend and headcount.
TNG462 Phase 1/2 monotherapy data update expected 2H 2025; registrational study in pancreatic cancer planned for 2026.
Combination trial of TNG462 with Revolution Medicines' RAS(ON) inhibitors daraxonrasib and zoldonrasib to begin enrollment Q2 2025.
TNG456 Phase 1/2 trial for glioblastoma enrollment expected Q2 2025; TNG260 clinical data update expected 2H 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.